Study unmasks a stem cell origin of skin cancer and the genetic roots of malignancy

Feb 03, 2011

A constellation of different stem cell populations within our skin help it to cope with normal wear and tear. By constantly proliferating, the stem cells allow skin to replenish itself, allowing each cell to be replaced by a new one about once a month. But the normal cycle of division and death within one or more of these stem cell types can sometimes be derailed by genetic mishaps. Such events are believed to spawn carcinomas and other deadly skin cancers, which are the mostly frequently diagnosed cancers in the United States.

Researchers at Cold Spring Harbor Laboratory (CSHL) led by Associate Professor Alea A. Mills, Ph.D., have now unmasked a long sought stem cell origin of carcinoma and identified the genetic lesions occurring within these that spur them on to . Her team has found that increased activity of a powerful called Ras combined with overly exuberant activity of a called ΔNp63α, stimulates the population of skin that produce keratin 15—one of many keratin proteins found in the skin—promoting carcinoma development. These findings appear online on February 4 in the journal Cell Stem Cell.

When cells in the skin or anywhere else in the body sense a potentially cancer-causing threat such as an activated oncogene like Ras—which speeds up cell division—the cells cope by slamming on the brakes to trigger a process called senescence. This is a tumor-suppressive mechanism that halts cell division while allowing cells to stay metabolically active.

"Unfortunately there are a number of genetic events that can bypass senescence and push a cell down the road towards cancer," says Mills. The loss of a gene called p53, a powerful tumor suppressor, in senescent cells is one such event.

Mills's group has long focused on p53's sister gene p63, which she discovered during her postdoctoral years. As Mills found subsequently, adult mice that lack p63 age faster, implicating this gene in aging-related processes. Like the other genes in its family, p63 has the ability to produce different protein versions or isoforms. Each of the six p63 isoforms is prevalent in different tissues and performs different functions.

In the skin, for example, TAp63 isoforms are predominantly found within the inner layers known as the dermis, where they guard against the formation of cancers known as sarcomas. The ΔNp63α isoform, on the other hand, is found within stem cells of the skin's outer layers—the epidermis—where it is essential for the cell proliferation needed for skin replenishment.

ΔNp63α has gained notoriety in recent years because it has been found to be present at very high levels in some types of human cancer, particularly squamous cell carcinoma, but is absent in other types of tumors, such as sarcomas. "This p63 isoform has been very perplexing," comments Mills.

"It was well known that Ras activation drives cells into senescence, but we found that as it does so, it exterminates levels of ΔNp63α. So we wondered what would happen if instead, there were excessive levels of ΔNp63α– a situation akin to that observed in the clinic in human carcinomas."

ΔNp63α obliterates oncogene-induced senescence

Mills' team investigated this question both in cultured cells—cells that they prepared from mouse skin and propagated in the lab—as well as in living mice. When cultured cells in which the Ras oncogene was switched on were also made to produce high levels of ΔNp63α, the cells overcame senescence and started dividing. Transplanting these cells from the lab dish to the skin of live mice caused robust formation.

To test ΔNp63α's cancer-causing role in vivo, the scientists induced Ras mutations in living mice by painting their skin with a carcinogenic compound called DMBA. The mice soon developed papillomas – harmless, pre-malignant lesions that resemble warts. The cells within these lesions were arranged into two zones: a layer of proliferating, healthy cells; and a region of senescent cells that formed when Ras mutations accumulated and caused levels of ΔNp63α to be driven down.

But eventually, the levels of ΔNp63α were beefed up in cells within the senescent zone, and as a result, provided a way to escape from senescence. Armed with ample ΔNp63α, these cells divided rampantly, eroding the senescent zone and turning lesions that were once harmless into malignant carcinomas.

Although the reason for the eventual increase in ΔNp63α levels in senescent cells remains unknown, the team was able to elucidate the mechanistic basis of ΔNp63α-triggered bypass of senescence. The culprit is a protein called LSH, which is known to regulate gene activity by controlling the way the cell's DNA is packaged.

"It appears that ΔNp63α is unshackling the cell from senescence by turning loose LSH, which in turn sets the stage for tumor progression," explains Mills. "Our experiments explain why ΔNp63α and LSH are both present at higher levels in human carcinomas."

ΔNp63α maintains the keratin 15-positive stem cell population

"A clue to its cancer-causing potential was that when ΔNp63α was turned on in the context of activated Ras, the cells took on 'stem-like' features, which was especially intriguing because this does not happen when senescence is bypassed by other means such as p53 depletion," according to Bill Keyes, Ph.D, a former postdoc in the Mills lab who is first author of this work and who now has his own research group at the Center for Genomic Regulation in Barcelona.

Following up on this stem cell link using cells from the skin of living mice that had been engineered to have their different skin stem cell populations tagged with different fluorescent colors, Keyes found that combined expression of activated Ras and ΔNp63α triggered abnormal proliferation of the stem cell population that produces the keratin 15 protein, while not affecting other stem cell populations.

"The net effect was to maintain this epithelial stem cell population over a longer period of time," says Mills. "This suggests that when present at high levels, ΔNp63α equips these cells with stem cell-like features, thereby giving them time to transform into cancerous cells."

ΔNp63α is already being used as a pathological marker in the clinic to distinguish between cancer subtypes. "This study adds a new dimension to what we know about p63's role in stem cell function and the contribution of its various isoforms in cancer," says Mills. "It also adds new insight to the role of stem cells in cancer by showing that when more mature progenitors or committed cells accumulate genetic lesions that make them more stem-like, they tend to promote cancer."

Explore further: Survival differences seen for advanced-stage laryngeal cancer

More information: "ΔNp63α Is an Oncogene that Targets Chromatin Remodeler Lsh to Drive Skin Stem Cell Proliferation and Tumorigenesis" appears in Cell Stem Cell on February 4.

Related Stories

How stem cells make skin

Sep 13, 2009

Stem cells have a unique ability: when they divide, they can either give rise to more stem cells, or to a variety of specialised cell types. In both mice and humans, a layer of cells at the base of the skin ...

Study: Skin cells turned into stem cells

Aug 22, 2005

The controversy over embryonic stem cell research may become moot with a procedure that turns skin cells into what appear to be embryonic stem cells.

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

16 hours ago

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

Hospital volume not linked to costs of cancer surgery

Nov 26, 2014

(HealthDay)—Hospital surgical volume does not appear to correlate with Medicare payments for cancer surgery, according to research published online Nov. 24 in the Journal of Clinical Oncology.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.